WuXi Biologics (Cayman) Inc. (2269.HK)
HKD 20.5
(1.49%)
HKD 20.5
(1.49%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.39 Billion CNY | -23.09% |
| 2022 | 4.42 Billion CNY | 30.45% |
| 2021 | 3.38 Billion CNY | 100.63% |
| 2020 | 1.68 Billion CNY | 66.59% |
| 2019 | 1.01 Billion CNY | 60.77% |
| 2018 | 630.59 Million CNY | 149.61% |
| 2017 | 252.62 Million CNY | 79.05% |
| 2016 | 141.09 Million CNY | 217.01% |
| 2015 | 44.5 Million CNY | 6.03% |
| 2014 | 41.97 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 749.54 Million CNY | 0.0% |
| 2024 Q1 | 749.54 Million CNY | 32.3% |
| 2023 Q1 | 1.13 Billion CNY | 20.23% |
| 2023 Q3 | 566.52 Million CNY | -50.01% |
| 2023 Q2 | 1.13 Billion CNY | 0.0% |
| 2023 FY | 3.39 Billion CNY | -23.09% |
| 2023 Q4 | 566.52 Million CNY | 0.0% |
| 2022 Q3 | 942.61 Million CNY | -25.63% |
| 2022 Q1 | 1.26 Billion CNY | 63.94% |
| 2022 FY | 4.42 Billion CNY | 30.45% |
| 2022 Q4 | 942.61 Million CNY | 0.0% |
| 2022 Q2 | 1.26 Billion CNY | 0.0% |
| 2021 Q2 | 921.07 Million CNY | 0.0% |
| 2021 Q3 | 773.16 Million CNY | -16.06% |
| 2021 Q4 | 773.16 Million CNY | 0.0% |
| 2021 FY | 3.38 Billion CNY | 100.63% |
| 2021 Q1 | 921.07 Million CNY | 93.35% |
| 2020 Q3 | 476.38 Million CNY | 29.43% |
| 2020 Q4 | 476.38 Million CNY | 0.0% |
| 2020 Q2 | 368.05 Million CNY | 0.0% |
| 2020 Q1 | 368.05 Million CNY | 30.57% |
| 2020 FY | 1.68 Billion CNY | 66.59% |
| 2019 Q2 | 225.02 Million CNY | 0.0% |
| 2019 FY | 1.01 Billion CNY | 60.77% |
| 2019 Q4 | 281.88 Million CNY | 0.0% |
| 2019 Q3 | 281.88 Million CNY | 25.27% |
| 2019 Q1 | 225.02 Million CNY | 18.11% |
| 2018 FY | 630.59 Million CNY | 149.61% |
| 2018 Q4 | 190.51 Million CNY | 0.0% |
| 2018 Q3 | 190.51 Million CNY | 52.67% |
| 2018 Q2 | 124.78 Million CNY | 0.0% |
| 2018 Q1 | 124.78 Million CNY | 55.56% |
| 2017 Q4 | 80.21 Million CNY | 0.0% |
| 2017 FY | 252.62 Million CNY | 79.05% |
| 2017 Q2 | 46.09 Million CNY | 0.0% |
| 2017 Q1 | 46.09 Million CNY | 848.92% |
| 2017 Q3 | 80.21 Million CNY | 74.01% |
| 2016 Q2 | 41.92 Million CNY | 0.0% |
| 2016 Q4 | 4.85 Million CNY | 0.0% |
| 2016 FY | 141.09 Million CNY | 217.01% |
| 2016 Q1 | 41.92 Million CNY | 20.46% |
| 2015 Q3 | 11.12 Million CNY | 0.0% |
| 2015 Q2 | 11.12 Million CNY | 0.0% |
| 2015 Q1 | 11.12 Million CNY | 0.0% |
| 2015 FY | 44.5 Million CNY | 6.03% |
| 2015 Q4 | 34.8 Million CNY | 212.8% |
| 2014 Q4 | 11.12 Million CNY | 6.03% |
| 2014 Q1 | 10.49 Million CNY | 0.0% |
| 2014 Q3 | 10.49 Million CNY | 0.0% |
| 2014 FY | 41.97 Million CNY | 0.0% |
| 2014 Q2 | 10.49 Million CNY | 0.0% |
| 2013 Q4 | 10.49 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | -4696.728% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | -19608.574% |